Sign in
Taking peoplePhase 2

Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS

Key facts

Who runs it
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
309 people, planned
Started
2 Feb 2026
Expected to end
Dec 2026
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • YD0743
  • YD0743 Placebo
Record updated
17 February 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Male or female, aged between 18 and 75 years (inclusive)
  • Diagnosis of sepsis
  • Diagnosis of Acute Respiratory Distress Syndrome (ARDS) suspected or confirmed to be caused by sepsis
  • Time from ARDS diagnosis to signing the informed consent form (ICF) does not exceed 48 hours
  • The subject (or their legally authorized representative) has fully understood the study's purpose, nature, procedures, and potential adverse events, voluntarily agrees to participate, and provides written informed consent

Who cannot take part

  • Known allergy or hypersensitivity to the active ingredient or any excipients of the investigational product; or a history of allergic disorders
  • Currently receiving or requiring Extracorporeal Membrane Oxygenation (ECMO) therapy
  • Thrombocytopenia at screening, active/uncontrolled bleeding, or patients whom the investigator considers to have a current or prior high risk of bleeding
  • Participation in other drug or medical device clinical trials within 3 months prior to this study, or current participation in another clinical trial
  • Currently diagnosed with active malignancy; or malignancy with distant metastasis; or cancer patients with cachexia; or patients with severe organ dysfunction or visceral hemorrhage due to tumor obstruction, space-occupying effect, or compression, for whom surgical intervention is difficult or has not yet been performed
  • Presence of chronic severe organ failure or immunodeficiency/immunosuppression
  • Positive for Hepatitis B surface antigen (HBsAg) with HBV-DNA > 1000 copies/mL or 200 IU/mL; positive for Hepatitis C virus antibody (HCV-Ab); positive for Human Immunodeficiency Virus antibody (HIV-Ab); or positive for Treponema pallidum antibody
  • Patients whose underlying primary disease cannot be effectively treated
  • Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study
  • Expected survival time is less than 48 hours at the time of screening
  • Sepsis with extensive burns as the primary cause
  • Diagnosis of neutropenia
  • Pregnant or breastfeeding women, or women planning to become pregnant within the next 6 months

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if YD0743 works to treat sepsis-associated acute respiratory distress syndrome (ARDS) in adult patients admitted to the Intensive Care Unit. It will also learn about the safety of drug YD0743. The main questions it aims to answer are:

Read full original descriptionShow less

Does YD0743 injection shorten the ventilator-using days in sepsis-associated ARDS patients? What medical problems do participants have when accepting YD0743 treatment?

Researchers will compare YD0743 to a placebo (a look-alike substance that contains no active drug) to see if YD0743 works to treat sepsis-associated ARDS.

Participants will:

Accepting YD0743 injection at least for 7 days. Visit the clinic in person at the Day 28 to receive the follow-up check (D1 is defined as the first day starting the YD0743 or placebo treatment) .

The 3 groups in the trial

  • Low-dose YD0743 groupTreatment being tested

    Each participant will receive low-dose YD0743 for 7-14 days.

    Treatment: YD0743

  • High-dose YD0743 groupTreatment being tested

    Each participant will receive high-dose YD0743 for 7-14 days.

    Treatment: YD0743

  • YD0743 Placebo groupPlacebo, for comparison

    Each participant will receive YD0743 Placebo for 7-14 days.

    Treatment: YD0743 Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Parallel, Randomized, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of YD0743 Injection in the Treatment of Sepsis-Associated Acute Respiratory Distress Syndrome
Criteria questions
Built from NCT07413094, who can take part
Record updated
17 February 2026